2nd European HIV Forum Glasgow – Presentation

 Next Generation of Antiretroviral Drugs: Oral Versus Injectable Delivery
 
Impact on: Adherence/tolerability
Dr. I. McGowan, University of Pittsburgh School of Medicine, USA
 
Impact on: Virology/Resistance
Dr. D. Kuritzkes, Harvard Medical School, USA
 
Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions
Dr. C. Fletcher, University of Nebraska Medical Center, USA
 Abstract presentations
 A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Positive, Antiretroviral-experienced Patients with Stable Viral Suppression
Dr. A. Borghetti, Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Italy
 Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients
Dr. B. Garrabé, AIDS Research Institute IrsiCaixa, Spain
 An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing
Dr. D. Armenia, University of Rome Tor Vergata, Italy
 French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network)
Dr. V. Calvez, Pitie-Salpetriere Hospital, Virology, France
 Tools to Improve the Clinician’s Management of Drug-Drug Interactions 
 
How to manage drug - drug interactions - the theory
Dr. G. Di Perri, University of Turin, Italy
 
Clinical Case Presentations – How to manage drug - drug interactions - the practice
Dr. A.M. Geretti, University of Liverpool, United Kingdom
 Drugs to Address Challenging Populations
 
Clinical Utility of Integrase Inhibitors during pregnancy
Dr. S. Khoo, University of Liverpool, United Kingdom
 Abstract presentations
 Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison
Dr. D. Descamps, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, France
 Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score
Dr. A. Borghetti, Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Italy
 Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison
Dr. I. Wijting, Erasmus Medical Center, the Netherlands
 Antiretroviral Treatment Strategies
 
Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO).
Dr. P. Cahn, Fundacion Huesped, Argentina
 
Clinical Case Presentations - Experience with Induction-Maintenance Therapy in real life settings
Dr. J. Arribas, Hospital Universitario La Paz, Spain
 Abstract presentation
 Maintenance Therapy with Dolutegravir/Rilpivirin is efficient and well tolerated in a real-life setting
Dr. K. Grabmeier-Pfistershammer, Institut of Immunology, Medical University Vienna, Austria